Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Under Investigation for Investors over Takeover

An investigation on behalf of investors of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) in connection with the proposed takeover was announced and NASDAQ:ARIA stockholders should contact the Shareholders Foundation.

Logo

San Diego, CA -- (SBWire) -- 01/20/2017 --The acquisition of Ariad Pharmaceuticals, Inc. is under investigation over possible wrongdoing. The investigation was announced for, who currently hold NASDAQ:ARIA shares, concerning whether the takeover of Ariad Pharmaceuticals, Inc. by Takeda Pharmaceutical Company Limited for $24.00 per share is unfair.

Investors who purch ased shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and currently hold any of those NASDAQ:ARIA shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Ariad Pharmaceuticals directors breached their fiduciary duties owed to NASDAQ:ARIA investors in connection with the proposed acquisition.

On January 9, 2017, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it has entered into an agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) under which Takeda Pharmaceutical Company will acquire all of the outstanding shares in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion,

However, the investigation concerns whether the offer is unfair to NASDAQ:ARIA stockholders. More specifically, the investigation concerns whether the Ariad Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On January 19, 2017, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) closed at $23.70 per share.

Those who are current investors in Ariad Pharmaceuticals, Inc. shares have certain options and should contact the Shareholders Foundation.

Media Relations Contact

Michael Daniels
General Manager
Shareholders Foundation
858-779-1554
http://www.ShareholdersFoundation.com

View this press release online at: http://rwire.com/762283